On March 25, 2026 Jecho Laboratories, Inc. reported it will present emerging preclinical data on JLC062, a novel B7-H3/PD-L1 bispecific antibody drug conjugate (bsADC) at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026. B7-H3 is a tumor-associated antigen highly expressed in solid tumors, while PD-L1 plays a key role in suppressing immune responses. JLC062 is composed of a fast-internalizing anti-B7-H3 arm and a non-internalizing anti-PD-L1 arm, which enables targeted delivery of a cytotoxic payload to tumors and disrupts immunosuppressive signaling while minimizing toxicity to immune cells. JLC062 is a promising therapeutic modality that integrates immune checkpoint inhibition with targeted cytotoxic delivery that may yield deep and durable antitumor responses.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The AACR (Free AACR Whitepaper) Annual Meeting will be held April 17-22, 2026 in San Diego, CA.
Details on the presentation are below. The full abstract can be found on the AACR (Free AACR Whitepaper) website.
Abstract 6561 /27: Rational design of a B7-H3/PD-L1 bsADC combining checkpoint blockade with targeted cytotoxicity for improved antitumor efficacy
Session Name: Clinical Research Track, Immune Checkpoint Blockade, PO.CL05.04
Session Time: Tuesday, April 21, 2026 2 – 5 p.m. PST
Location: San Diego Convention Center, Poster Section 44
(Press release, Jecho Laboratories, MAR 25, 2026, View Source [SID1234664150])